Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
Locksley Resources Ltd. is pleased to announce a significant Company milestone with the production of a 100% American made antimony ingot, marking the return of the first U.S domestic antimony metal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback